international medical conferences
international medical conferences with http://www.md-news.net

international medical conferences

MD News

News for 09-Dec-24

Source: MedicineNet Senior Health General
Health Tip: Reduce Your Risk of Hip Fracture

Source: MedicineNet Senior Health General
Prices Skyrocket on Drugs Widely Used by Seniors: Report

Source: MedicineNet Senior Health General
Electronic In-Hospital Prescribing: Trouble for Older Adults?

Source: MedicineNet Prevention and Wellness General
Vitamin D Supplements: Is What You See What You Get?

Search the Web
international medical conferences
maui medical conferences
procurement of medical supplies
puget sound medical supplies
remedy yale medical supplies
saint johns medical supplies
scooters
sell medical supplies
supplies
surgical supplies

The Best international medical conferences website

All the international medical conferences information you need to know about is right here. Presented and researched by http://www.md-news.net. We've searched the information super highway far and wide to provide you with the best international medical conferences site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
international medical conferences.

international medical conferences

MD News
Need information on medical news? Follow our sponsored links to find information on all of your medical new needs.
MD News

Although our site may not be of the same high quality of the site listed above, we believe that given time this international medical conferences site will be one of the major international medical conferences sites on the internet. After all we are relatively new to the e-commerce industry and are striving to reach perfection.

Personally I have my doubts about whether we'll succeed. These international medical conferences websites are easily the very best that you will ever come across. In fact you could do what we did and search the Internet by day and by night without coming across something across something that meets your needs better. So I guess that you had better click on one of the hyperlinks and leave us behind. Come back again one day though, because we're improving the level of international medical conferences information every day.

international medical conferences

MD News
Need information on medical news? Follow our sponsored links to find information on all of your medical new needs.
MD News

Thousands of international medical conferences e-stores now thrive on the Web, providing people with a way to purchase goods and services electronically. For small businesses, the Internet can deliver a global market. Depending on which survey you believe, that may be more than 350 million people, with another 500 million Internauts projected over the next few years. If the demographics of the online community match your international medical conferences customer profile, that's a lot of potential new business. While the potential is there, however, challenges loom large.

Remember, it takes time for people to adopt to new technology and modes of transactions. Many people remain reluctant to give out their credit card numbers over the Internet for international medical conferences purchases. But most analysts project healthy growth for international medical conferences online sales, especially as security issues are addressed.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
MD Meetings | Doctors On-the-Net | Kids Meet | medical mailings | Medical Newscast

Medical Meetings   Talk On The Net   Fantasy Football Update